Indeed, since TGF‐β is a soluble growth hormone that is ubiquitously present throughout the body, an anti‐TGF‐β mAb is unlikely to be preferentially retained within the tumor milieu, even if the mAb extravasates from the tumor vasculature. Here, TGFB1 is linked to neoplasm.